Larvol Delta - FDA-Accepts-MyMD-Pharmaceuticals-Investigational-New-Drug-Application-IND-for-Phase-2-Study-of-oral-TNF-inhibitor-MYMD1-in-Rheumatoid-Arthritis-RA

isomyosamine (MYMD-1) - MyMD Pharma, Akers Biosci

https://www.businesswire.com/news/home/20230814042365/en/FDA-Accepts-MyMD-Pharmaceuticals%E2%80%99-Investigational-New-Drug-Application-IND-for-Phase-2-Study-of-oral-TNF-%CE%B1-inhibitor-MYMD-1%C2%AE-in-Rheumatoid-Arthritis-RA

Aug 14, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next